Top

Published in:

01-10-2019 | Osteoarthrosis

Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity

Authors: L. M. Fatti, B. Cangiano, G. Vitale, L. Persani, G. Mantovani, E. Sala, M. Arosio, P. Maffei, F. Dassie, M. Mormando, A. Giampietro, L. Tanda, E. R. Masiello, E. Nazzari, D. Ferone, S. Corbetta, E. Passeri, F. Guaraldi, S. Grottoli, S. Cannavò, M. L. T. Torre, D. Soranna, A. Zambon, F. Cavagnini, M. Scacchi, The Study Group on Motor Disability in Acromegaly of the Italian Society of Endocrinology

Published in: Pituitary | Issue 5/2019

Abstract

Purpose

Arthropathy is a common and disabling complication of acromegaly. Since in this condition radiological findings rarely correspond to functional impairment, we elected to quantify in a large cohort of acromegalic patients: the degree of motor disability compared with data from general population, the impact of joint involvement on quality of life and work productivity, and to look for associated factors.

Methods

In 211 acromegalic patients, 131 with controlled disease and 80 with active disease, eight validated scales were used to evaluate the (i) prevalence and distribution of arthropathy, (ii) degree of motor disability and joint symptoms (VAS, AIMS symptoms and WOMAC), (iii) quality of life (AcroQoL and PASQ) and work capability (WPAI:GH) as consequences of joint complications.

Results

Using the WOMAC questionnaire, for which population based normative values are available, a significantly higher prevalence and severity of motor disability was detected in acromegalics compared to the general population from literature. The results provided by the different questionnaires turned out to be highly concordant. All measures of motor disability correlated both with impaired quality of life and motor disability and were worse in females and in patients with higher BMI.

Conclusions

The questionnaires VAS, AIMS symptoms, and WOMAC (this latter both as a whole and with its functionality subscale), with their scores, proved to be the most adequate tools to evaluate motor disability and its consequences on both quality of life and work productivity in acromegaly. Female gender and higher BMI are associated with worse articular symptoms.

Colao A, Pivonello R, Scarpa R et al (2005) The acromegalic arthropathy. J Endocrinol Invest 28:24–31CrossRefPubMed

Claessen KMJA, Mazziotti G, Biermasz NR, Giustina A (2015) Bone and joint disorders in acromegaly. Neuroendocrinology 103(1):86–95. https://doi.org/10.1159/000375450 CrossRefPubMed

Wassenaar MJE, Biermasz NR, Bijsterbosch J et al (2011) Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 70:320–325. https://doi.org/10.1136/ard.2010.131698 CrossRefPubMed

Biermasz NR, van’t Klooster R, Wassenaar MJE et al (2012) Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol 166:407–413. https://doi.org/10.1530/EJE-11-0795 CrossRefPubMed

Scarpa R, De Brasi D, Pivonello R et al (2004) Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab 89:598–603. https://doi.org/10.1210/jc.2003-031283 CrossRefPubMed

Bluestone R, Bywaters EG, Hartog M et al (1971) Acromegalic arthropathy. Ann Rheum Dis 30:243–258CrossRefPubMedPubMedCentral

Lieberman SA, Björkengren AG, Hoffman AR (1992) Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 21:615–631CrossRefPubMed

Wassenaar MJE, Biermasz NR, Kloppenburg M et al (2010) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res 20:226–233. https://doi.org/10.1016/j.ghir.2010.02.003 CrossRefPubMed

Claessen KMJA, Ramautar SR, Pereira AM et al (2014) Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary 17:44–52. https://doi.org/10.1007/s11102-013-0464-6 CrossRefPubMed

10.

Claessen KMJA, Kloppenburg M, Kroon HM et al (2013) Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res 23:159–164. https://doi.org/10.1016/j.ghir.2013.05.003 CrossRefPubMed

11.

Claessen KMJA, Ramautar SR, Pereira AM et al (2012) Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol 167:235–244. https://doi.org/10.1530/EJE-12-0147 CrossRefPubMed

12.

Webb SM, Badia X, Spanish AcroQol Study Group (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155:269–277. https://doi.org/10.1530/eje.1.02214 CrossRefPubMed

13.

Badia X, Webb SM, Prieto L, Lara N (2004) Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2:13. https://doi.org/10.1186/1477-7525-2-13 CrossRefPubMedPubMedCentral

14.

Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177. https://doi.org/10.1056/NEJM200004203421604 CrossRefPubMed

15.

Neggers SJCMM, Van Aken MO, De Herder WW et al (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93:3853–3859. https://doi.org/10.1210/jc.2008-0669 CrossRefPubMed

16.

Ohnhaus EE, Adler R (1975) Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain 1:379–384CrossRefPubMed

17.

Sriwatanakul K, Kelvie W, Lasagna L et al (1983) Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 34:234–239CrossRefPubMed

18.

Meenan RF, Gertman PM, Mason JH, Dunaif R (1982) The arthritis impact measurement scales. Further investigations of a health status measure. Arthritis Rheum 25:1048–1053CrossRefPubMed

19.

Cavalieri F, Salaffi F, Ferraccioli GF (1991) Relationship between physical impairment, psychological variables and pain in rheumatoid disability. An analysis of their relative impact. Clin Exp Rheumatol 9:47–50PubMed

20.

Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840

21.

Salaffi F, Leardini G, Canesi B et al (2003) Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthr Cartil 11:551–560CrossRefPubMed

22.

Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186CrossRef

23.

Katz S, Ford AB, Moskowitz RW et al (1963) Studies of illness in the aged. The index of adl: a standardized measure of biological and psychosocial function. JAMA 185:914–919CrossRef

24.

Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353–365. https://doi.org/10.2165/00019053-199304050-00006 CrossRefPubMed

25.

Leggett S, van der Zee-Neuen A, Boonen A et al (2016) Test-retest reliability and correlations of 5 global measures addressing at-work productivity loss in patients with rheumatic diseases. J Rheumatol 43:433–439. https://doi.org/10.3899/jrheum.141605 CrossRefPubMed

26.

Bellamy N, Wilson C, Hendrikz J (2011) Population-based normative values for the Western Ontario and McMaster (WOMAC) Osteoarthritis Index: Part I. Semin Arthritis Rheum 41:139–148. https://doi.org/10.1016/j.semarthrit.2011.03.002 CrossRefPubMed

27.

Chuang-Stein C (1992) Summarizing laboratory data with different reference ranges in multi-center clinical trials. Drug Inf J 26:77–84. https://doi.org/10.1177/009286159202600108 CrossRef

28.

Kropf LL, Madeira M, Neto LV et al (2013) Functional evaluation of the joints in acromegalic patients and associated factors. Clin Rheumatol 32:991–998. https://doi.org/10.1007/s10067-013-2219-1 CrossRefPubMed

29.

Biermasz NR, Pereira AM, Smit JW, Romijn JA et al (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90:2731–2739. https://doi.org/10.1210/jc.2004-2297 CrossRefPubMed

30.

Johnson VL, Hunter DJ (2014) The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 28:5–15. https://doi.org/10.1016/J.BERH.2014.01.004 CrossRefPubMed

31.

Claessen KMJA, Canete AN, de Bruin PW et al (2017) Acromegalic arthropathy in various stages of the disease: an MRI study. Eur J Endocrinol 176:779–790. https://doi.org/10.1530/EJE-16-1073 CrossRefPubMed

32.

Layton MW, Fudman EJ, Barkan A et al (1988) Acromegalic arthropathy. Characteristics and response to therapy. Arthritis Rheum 31:1022–1027CrossRefPubMed

Title: Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity
Authors: L. M. Fatti
B. Cangiano
G. Vitale
L. Persani
G. Mantovani
E. Sala
M. Arosio
P. Maffei
F. Dassie
M. Mormando
A. Giampietro
L. Tanda
E. R. Masiello
E. Nazzari
D. Ferone
S. Corbetta
E. Passeri
F. Guaraldi
S. Grottoli
S. Cannavò
M. L. T. Torre
D. Soranna
A. Zambon
F. Cavagnini
M. Scacchi
The Study Group on Motor Disability in Acromegaly of the Italian Society of Endocrinology
Publication date: 01-10-2019
Publisher: Springer US
Keywords: Osteoarthrosis
Acromegaly
Osteoarthrosis
Dopamine Agonist
Published in: Pituitary / Issue 5/2019
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-019-00966-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2019

Ipilimumab-induced hypophysitis, a single academic center experience

Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers

Craniopharyngiomas presenting as incidentalomas: results of KRANIOPHARYNGEOM 2007

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

Peel-off resection of the pituitary gland for functional pituitary adenomas: pathological significance and impact on pituitary function

Static and dynamic balances of patients with acromegaly and impact of exercise on balance

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page